A Phase III, Randomized, Double-Blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Naive HIV-1 Infected Subjects

Trial Profile

A Phase III, Randomized, Double-Blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Naive HIV-1 Infected Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Rilpivirine (Primary) ; Abacavir; Efavirenz; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms THRIVE
  • Sponsors Tibotec Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Apr 2014 Results from a 96-week pooled analysis published in the Clinical Infectious Diseases.
    • 10 Dec 2012 The US FDA has approved a prescribing information update for rilpivirine to include 96-week pooled data from ECHO and THRIVE, according to a Janssen Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top